U.S. Markets open in 6 hrs 50 mins

Immunogen Inc (IMGN) Files 10-K for the Fiscal Year Ended on December 31, 2018

- By insider

Immunogen Inc (IMGN) files its latest 10-K with SEC for the fiscal year ended on December 31, 2018. Immunogen Inc is a clinical-stage biotechnology company that develops targeted anticancer therapeutics. It has developed its ADC technology to enable the creation of anticancer products. Immunogen Inc has a market cap of $374.218 million; its shares were traded at around $2.51 with and P/S ratio of 4.12.

For the last quarter Immunogen Inc reported a revenue of $13.8 million, compared with the revenue of $39.45 million during the same period a year ago. For the latest fiscal year the company reported a revenue of $53.8 million, a decrease of 53.4% from the previous year. For the last five years Immunogen Inc had an average revenue growth rate of 11.1% a year.

The reported loss per diluted share was $1.2 for the year, compared with the loss per share of $0.71 in the previous year. The Immunogen Inc had an operating margin of -291.34%, compared with the operating margin of -50.42% a year before. The 10-year historical median operating margin of Immunogen Inc is -162.45%. The profitability rank of the company is 4 (out of 10).

At the end of the fiscal year, Immunogen Inc has the cash and cash equivalents of $262.3 million, compared with $267.1 million in the previous year. The company had no long term debt, compared with $2.05 million in the previous year. Immunogen Inc has a financial strength rank of 5 (out of 10).

At the current stock price of $2.51, Immunogen Inc is traded at 73.7% discount to its historical median P/S valuation band of $9.54. The P/S ratio of the stock is 4.12, while the historical median P/S ratio is 15.61. The stock lost 77.2% during the past 12 months.

For the complete 20-year historical financial data of IMGN, click here.

This article first appeared on GuruFocus.